Connect with us

Business

American Express Shares Rebound 2.4% After Q2 Beat as Company Pours Profits Into Growth Initiatives

Published

on

Wix Stock Jumps Nearly 10% as Battered Shares Rebound Ahead

NEW YORK — Shares of American Express Co. climbed 2.41% to $334.04 in midday trading Monday, recovering some ground lost after the payments giant reported stronger-than-expected second-quarter results last week but kept its full-year profit outlook unchanged while signaling higher spending on growth.

The stock rose $7.87 as of 11:05 a.m. EDT on July 27, according to market data, following a roughly 6% drop on July 24 when investors focused on rising expenses and the company’s decision to reinvest first-half outperformance rather than boost near-term earnings guidance. American Express closed Friday at about $326.

On July 24, the New York-based company reported second-quarter net income of $3.1 billion, or $4.53 per diluted share, up 11% from $2.9 billion, or $4.08 per share, a year earlier. Revenue net of interest expense rose 10% to $19.6 billion. Both figures topped Wall Street expectations, with analysts looking for roughly $4.40 in earnings per share and slightly higher revenue.

Billed business, a key measure of card member spending, increased 9% to $455.8 billion, the strongest growth rate in three years on a foreign-exchange-adjusted basis. Net card fees climbed 15% to about $2.9 billion, marking the 32nd consecutive quarter of double-digit growth in that line. Provisions for credit losses fell to $1.1 billion from $1.4 billion a year earlier, reflecting a reserve release amid stable credit quality. The net write-off rate held at 2.0%.

Advertisement

Consolidated expenses, however, rose 12% to $14.5 billion, driven by higher variable customer engagement costs tied to increased spending, the U.S. Platinum Card refresh, greater use of card benefits, and elevated operating expenses. Management indicated marketing expenses would run about 10% higher in the second half of the year compared with the prior year.

American Express raised its full-year 2026 revenue growth guidance to 10% from a previous range of 9% to 10%. It reaffirmed earnings-per-share guidance of $17.30 to $17.90. For the first six months of 2026, revenue net of interest expense rose 11% to $38.5 billion, and diluted earnings per share increased 14% to $8.81.

Chairman and Chief Executive Officer Stephen J. Squeri described the quarter as another strong performance. “We had another excellent quarter, with 10 percent revenue growth, EPS of $4.53, and Card Member spending growth of 9 percent, the highest rate we’ve seen in three years on an FX-adjusted basis,” Squeri said in the company’s earnings release. “Based on our better-than-expected performance in the first half of the year, we are raising our full-year revenue growth guidance to 10 percent and plan to reinvest this outperformance in growth initiatives given the significant opportunities we see ahead. We continue to expect full-year EPS of $17.30 to $17.90.”

He added: “Six months into the year, we’re seeing stronger momentum than we expected. The investments we made in our value propositions have driven accelerated spend and revenue growth; our Platinum portfolio is now the fastest growing in our U.S. Consumer business; our best-in-class credit performance further strengthened; and we continued to attract a large number of new customers, particularly Millennials and Gen-Zs who represent greater lifetime value.”

Advertisement

On the earnings call, Squeri addressed why the company chose not to raise the profit outlook despite the revenue lift. “We have a choice, we can either drop the overperformance to the bottom line and buy back more shares, or we can invest to grow the business,” he told analysts. “We’ve chosen the latter because, in the long run, it is the one that creates the most value for our shareholders.”

The company added about 3 million new cards in the quarter. More than 70% of new accounts acquired year-to-date were on fee-based products, with the proportion reaching about 75% in the second quarter—the highest level since the intensified focus on premium offerings. U.S. consumer services revenue rose 11%, commercial services 7%, and international card services 12%. Travel and entertainment spending grew 10%, with restaurants, hotels, and airlines contributing. Travel bookings jumped 22%.

American Express returned roughly $2.9 billion to shareholders in the quarter through share repurchases and dividends. It bought back about 7 million shares for $2.2 billion and paid $600 million in dividends. The Common Equity Tier 1 capital ratio stood at 10.4%, and return on average equity reached 36.4% for the quarter.

The company also highlighted strategic moves. It announced a proposed acquisition of TheFork, a European restaurant booking platform with about 50,000 restaurants across 11 countries, for roughly $700 million. It expanded partnerships, including a global deal with ALL Accor, became the official payments partner of Fanatics at select locations, enabled Membership Rewards points redemption for Apple Pay checkouts by U.S. card members, and introduced new travel benefits for Delta SkyMiles cardholders. It also piloted a new expense management platform for middle-market commercial customers.

Advertisement

Chief Financial Officer Christophe Le Caillec noted the company plans to reinvest overperformance into marketing and growth to support and accelerate momentum. Credit metrics remained solid, with delinquency and write-off rates still below 2019 levels. Executives said they saw no broad slowdown in spending among their premium customer base despite economic uncertainty, though middle-market commercial activity showed some softness while small business and large corporate remained stronger.

Analysts and investors initially reacted to the expense growth and flat profit guidance with selling pressure. Shares fell more than 6% on the results day as the market weighed higher near-term costs against the raised revenue outlook and robust spending trends among affluent cardholders. Monday’s rebound suggested some investors were looking past the short-term margin pressure toward the company’s longer-term strategy of refreshing premium products, acquiring higher-value younger customers, and expanding its ecosystem of benefits and partnerships.

American Express has emphasized its Membership Model centered on premium products, differentiated services, and partnerships. The U.S. Platinum Card refresh has driven engagement and spend consolidation among existing members. Net interest income rose 11% on higher card balances, though portfolio sales created a modest headwind. The effective tax rate was 23.6%, up from 18.7% a year earlier due to prior-year discrete benefits.

Looking ahead, management expects card fee growth to accelerate in the third quarter and exit the year in the high teens. The company continues to invest in technology, including AI capabilities for internal efficiency and customer experiences, and remains open to additional investment opportunities. Squeri has described the current environment as still early for transformative AI impacts, likening it to the “preseason.”

Advertisement

The stock’s 52-week range has run from about $288 to $387. Market capitalization stood near $223 billion following Friday’s close. Dividend yield hovered around 1.1%, with a recent quarterly dividend of 95 cents per share.

American Express’s results underscore resilience in premium consumer spending on travel, dining, and entertainment even as broader economic signals remain mixed. By choosing to reinvest rather than maximize near-term profits, the company is betting that sustained investment in its value propositions, customer acquisition—especially among Millennials and Gen Z—and ecosystem partnerships will deliver stronger long-term returns. Monday’s share price recovery indicated that at least some market participants were beginning to price in that longer view after digesting the details of the quarterly report.

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Kiniksa Pharmaceuticals Shares Surge 21% on Strong ARCALYST Sales and Raised 2026 Guidance

Published

on

Microsoft buys Activision, in New York City

BOSTON — Shares of Kiniksa Pharmaceuticals International plc jumped more than 21% in morning trading Tuesday after the biopharmaceutical company reported second-quarter results that exceeded expectations and raised its full-year sales outlook for its flagship drug treating recurrent pericarditis.

Kiniksa stock rose $13.43, or 21.14%, to $76.97 as of 10:06 a.m. EDT on the Nasdaq. The move came after the company announced ARCALYST (rilonacept) net product revenue of $243.6 million for the quarter ended June 30, representing approximately 55% growth from the same period a year earlier. The figure surpassed analyst estimates.

The company also increased its expected 2026 ARCALYST net product revenue guidance to a range of $980 million to $995 million, up from the previous range of $930 million to $945 million. Kiniksa reported net income of $25.4 million for the quarter and ended the period with $525.9 million in cash, cash equivalents and short-term investments, and no debt.

In a statement accompanying the results, the company highlighted continued commercial momentum. Approximately 21% of the estimated 14,000 multiple-recurrence recurrent pericarditis patients in the United States were actively on ARCALYST therapy at the end of the second quarter. More than 5,000 prescribers have written prescriptions for the drug since its launch in the indication.

Advertisement

“In the second quarter, Kiniksa continued to drive growth in new and repeat prescribers of ARCALYST in recurrent pericarditis,” the company said in its earnings release. The results reflect expanding adoption of the only FDA-approved therapy specifically indicated for the condition, a painful and debilitating autoinflammatory cardiovascular disease characterized by inflammation of the pericardium.

Beyond the commercial performance, Kiniksa provided an update on its pipeline. An interval analysis from the Phase 2 dose-focusing portion of the KPL-387 Phase 2/3 trial in recurrent pericarditis showed rapid and sustained reductions in pain and inflammation at the 300 mg subcutaneous once-monthly dose selected for Phase 3. Time to treatment response was a median of 4.0 days, and time to C-reactive protein normalization was a median of 8.0 days. Efficacy was durable throughout the monthly dosing interval, and the drug was generally well-tolerated, consistent with the known safety profile of interleukin-1 pathway inhibition.

The company has initiated and is dosing patients in PASTORALE, the pivotal Phase 3 randomized withdrawal trial evaluating KPL-387 300 mg subcutaneous once-monthly in a liquid formulation. Kiniksa targets potential commercialization of KPL-387 in the 2028-2029 timeframe. It also remains on track to initiate a Phase 1 first-in-human trial for KPL-1161, an Fc-modified IL-1 antagonist designed for once-quarterly dosing, by the end of 2026.

Sanj K. Patel, Kiniksa’s chief executive officer, commented on the dual progress in commercialization and clinical development. “In our clinical portfolio, KPL-387 Phase 2 data supported initiation of the pivotal Phase 3 trial, PASTORALE, which is now enrolling and dosing patients. We are excited to advance KPL-387 with its target product profile of once-monthly subcutaneous dosing in a liquid formulation. We expect to bring this potential additional treatment option to patients in the 2028/2029 timeframe. Additionally, we continue to develop KPL-1161 with a target profile of once-quarterly dosing and are on track to initiate a Phase 1 trial by the end of this year.”

Advertisement

The strong quarterly performance builds on earlier 2026 momentum. In the first quarter, ARCALYST revenue had already shown robust growth, prompting a previous upward revision to guidance. The further increase announced Tuesday signals confidence that underlying demand remains solid and that market penetration has room to expand. Recurrent pericarditis affects an estimated larger patient population beyond the multiple-recurrence segment currently being captured, and earlier treatment approaches could further broaden the addressable market over time.

Kiniksa focuses on developing and commercializing therapies for diseases with unmet need, with particular emphasis on cardiovascular indications. ARCALYST, an interleukin-1 alpha and beta cytokine trap, received FDA approval for recurrent pericarditis and has become the cornerstone of the company’s revenue. The pipeline assets KPL-387 and KPL-1161 aim to offer differentiated dosing convenience while targeting the same validated IL-1 pathway.

Analysts had anticipated solid results given the trajectory of ARCALYST prescriptions and the limited competition in the recurrent pericarditis space. The combination of a clear revenue beat, a meaningful guidance raise, positive mid-stage data and Phase 3 initiation provided multiple catalysts that investors rewarded with a sharp revaluation of the shares. The stock had already risen substantially year-to-date prior to the report, reflecting growing recognition of the commercial potential of ARCALYST and the strategic value of the IL-1 franchise.

The company expects its current operating plan to remain cash-flow positive on an annual basis. With a strengthened balance sheet and no debt, Kiniksa is positioned to fund ongoing commercial efforts and clinical development without near-term financing needs. Management is scheduled to discuss the results further on a conference call and webcast.

Advertisement

Investors will continue to monitor prescription trends, the pace of new prescriber adoption and any updates from the PASTORALE trial. Success with KPL-387 could eventually provide a next-generation option with less frequent dosing than ARCALYST’s weekly regimen, potentially expanding the franchise. For now, the second-quarter numbers and raised outlook underscore that the existing product continues to gain traction in a market that remains underpenetrated.

The rapid share-price reaction underscores the market’s sensitivity to execution in rare-disease commercialization and clear clinical progress. Kiniksa’s results arrive amid a broader biotech environment in which companies demonstrating both commercial traction and pipeline advancement have often been rewarded. The day’s gains place the stock near the upper end of its 52-week range as the company advances its dual commercial and development strategy in cardiovascular inflammation.

Continue Reading

Business

Rescuers in Japan haul survivors from collapsed mall as earthquake toll rises to 13

Published

on


Rescuers in Japan haul survivors from collapsed mall as earthquake toll rises to 13

Continue Reading

Business

Liontown Limited (LINRF) Q4 2026 Earnings Call Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript